Technologies

Researchers at the University of South Florida have developed a new anti-cancer vaccine for treatment of a wide range of cancers. In vitro and in vivo data indicate that the vaccine developed by our investigators targets Stat3 activity in tumor cells, which allows the tumor cells to produce pro-inflammatory cytokines that activate immune cells, such as dendritic cells cytotoxic Tcells, and macrophages. These activated immune cells are then able to recognize and eliminate tumor cells in the patient. Stat3 activity is high in a variety of tumor cells, so this technology has great potential as a therapeutic anticancer vaccine for a range of cancer types, including, but not limited to colon, breast, bladder, prostate, and lung cancers.